Home Tags Monomethyl auristatin E

Tag: monomethyl auristatin E

Merck Acquires VelosBio and Strengthens Oncology Pipeline with Investigational Antibody-Drug Conjugates

Merck & Co (MSD) has agreed to acquire VelosBio, a privately held clinical-stage biopharmaceutical company, for U.S. $ 2.75 billion in cash, subject to...

A Novel Platform for the Generation of Site-Specific Antibody−drug Conjugates

Antibody-drug conjugates (ADCs) combine the superior selectivity of antibodies with the high potency of cytotoxic agents. With 9 approved and commercially available ADCs for...

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin ...

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy in patients with previously treated...

Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in...

A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival (OS) compared to chemotherapy.Globally, approximately...

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development...

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize ladiratuzumab vedotin an investigational antibody-drug...

Disitamab Vedotin Shows Clinically Meaningful Response and Survival Benefit in Heavily...

Data from a phase II study of disitamab vedotin (previously known as RC48) shows clinically meaningful results in the treatment of heavily pretreated patients...
Photo: Photo ASCO meeting. Photo Courtesy: ASCO/Todd Buchanan 2015

ASCO 2020 – Promising Development in the Advancement of Antibody-drug Conjugates

With an increasing number of antibody-drug conjugates (ADC) being approved and commercially available for the treatment of patients with cancer and hematological malignancies, the...

FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin-ejfv in First-Line Advanced...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with...

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with pembrolizumab (Keytruda®; Merck Sharp &...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)* for the treatment of adult...